Clinically insignificant improvement of prostate cancer prediction by addition of sex steroid hormones and SHBG serum levels to serum PSA, fPSA%, and age in a screening setting

2012 ◽  
Vol 11 (2) ◽  
Author(s):  
Isabel Heidegger ◽  
Marina Popovscaia ◽  
Reinhold Ramoner ◽  
Georg Schäfer ◽  
Birgit Stenzel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Steroid Hormones ◽  
Specific Antigen ◽  
Free Testosterone ◽  
Serum Levels ◽  
Sex Hormone Binding Globulin ◽  
Sex Steroid ◽  
Sex Steroid Hormone ◽  
Cancer Prediction ◽  
Free Psa

AbstractVarious findings implicate sex hormones in prostate growth and development and also in prostate carcinogenesis. We investigated if addition of sex steroid hormone and sex hormone binding globulin (SHBG) serum levels to standard risk assessment parameters [prostate-specific antigen (PSA), free PSA percentage (fPSA%), and age] improves prostate cancer prediction in a PSA screening setting. Steroid hormones testosterone (T), free testosterone (fT), and estradiol (E2), and binding protein SHBG levels were measured in 762 men undergoing prostate biopsy due to suspect PSA serum levels. Prostate cancer was diagnosed in 286 (37.5%) of these men. Our data confirmed that PSA (mean BE=5.09; mean CA=6.05; p=1.24×10

Reproductive Dysfunction in Women With Epilepsy: Antiepileptic Drug Effects on Sex-Steroid Hormones

CNS Spectrums ◽  
2001 ◽  
Vol 6 (9) ◽  
pp. 771-786 ◽  
Author(s):  
Martha J. Morrell ◽  
Kerry L. Flynn ◽  
Cairn G. Seale ◽  
Silvia Doñe ◽  
Amelia J. Paulson ◽  
...  
Keyword(s):  
At Risk ◽  
Cytochrome P450 ◽  
Steroid Hormones ◽  
Drug Effects ◽  
Free Testosterone ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Cytochrome P450 Enzymes ◽  
Sex Steroid Hormone ◽  
Reproductive Aged Women

ABSTRACTWomen with epilepsy are at risk for reproductive health dysfunction. Sex-steroid hormone abnormalities have been reported in women with epilepsy, but it has been difficult to determine whether these abnormalities are due to epilepsy-related hypothalamic-pituitary axis dysfunction, or to pharmacokinetic actions of antiepileptic drugs (AEDs). Sex-steroid hormones were evaluated in 84 reproductive-aged women with epilepsy receiving an AED in monotherapy, and in 20 nonepileptic controls. Estrone, free testosterone, and androstenedione were significantly lower in subjects receiving enzyme-inducing AEDs than in nonepileptic controls. Free testosterone was significantly elevated in subjects receiving valproate compared to nonepileptic controls. Subjects with epilepsy receiving gabapentin or lamotrigine were no different from the nonepileptic controls in any of the endocrine variables. Subjects with epilepsy who are receiving AEDs that alter cytochrome P450 enzymes are at risk for significant abnormalities in sex-steroid hormones. In contrast, subjects receiving AEDs that do not alter cytochrome P450 enzymes show no differences in sex-steroid hormones compared with nonepileptic controls. With new AEDs available that do not alter cytochrome P450 enzymes, physician selection of therapy should consider not only seizure control, but also potential effects on reproductive physiology.

scholarly journals The Weight of HLA-DPA1 rs3077 Single Nucleotide Polymorphism in Prostate Cancer, a Multicenter Study

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Mohammed Jayed Alenzi ◽  
Amany A. Ghazy ◽  
Diaa-Eldin Taha
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Serum Levels ◽  
Arab Countries ◽  
Control Group ◽  
Single Nucleotide ◽  
Genetic Transmission ◽  
Free Psa ◽  
Protective Allele ◽  
Total Prostate Specific Antigen

Prostate cancer (PCa) has almost the highest genetic transmission that mimics an autosomal dominance hereditary pattern of cancers in some families. Its incidence in Arab countries was reported to be steadily increasing. Aim. To determine the relevance of HLA-DPA1 rs3077 (A/G) SNP with prostate cancer’s risk and/or severity. Subjects and Methods. Forty PCa patients and forty age matched patients with benign prostatic hyperplasia (BPH), as a control group, were enrolled in the study. Serum levels of urea, creatinine, total prostate-specific antigen (PSA), and free PSA were measured. PSA ratio was determined as well. Genotyping of HLA-DPA1 rs3077 (A/G) SNP was done using real-time PCR. Results. The measured lab parameters, except free PSA, were significantly higher among PCa patients in comparison to controls ( P < 0.001 ∗ ). Moreover, PSA ratio was significantly high among PCa patients ( P < 0.001 ∗ ). HLA-DPA1 rs3077 GG genotype was more frequent in PCa patients and the associated OR was 2.546 ( P = 0.059 ), while AA genotype was more frequent in the control group and the associated OR was 0.145 ( P = 0.081 ). Frequency of G allele was higher among PCa patients than the control group while A allele frequency was significantly decreased ( P = 0.034 ∗ ) (protective allele). On multivariate analysis, there is no significant correlation found between HLA-DPA1 rs3077 SNP and PSA ratio (OR = 4.5, 95% CI = 1.2–17.4, P = 0.856 ). Conclusion. HLA-DPA1 rs3077 G allele could be a risk factor for prostate cancer. However, HLA-DPA1 rs3077 SNP has no relation to PCa severity.

Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC).

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 162-162
Author(s):  
Christoph W. Reuter ◽  
Michael A. Morgan ◽  
Martin Fenner ◽  
Viktor Grünwald ◽  
Arnold Ganser
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Disease Progression ◽  
Salvage Therapy ◽  
Specific Antigen ◽  
Free Testosterone ◽  
Serum Levels ◽  
Castration Resistant Prostate Cancer ◽  
Psa Response ◽  
The Impact

162 Background: Our recent data have shown that carboplatin AUC5 on d1 plus docetaxel at a dose of 35 mg/m2 iv on d1, 8, 15 every 4 weeks (q4w) is an effective salvage therapy in mDRPC. Patients (pts) who have progressive disease during DC treatment survive only ~7 months and many are symptomatic. We have demonstrated that high free testosterone (FT) serum levels during DC treatment have a negative prognostic value for PSA response and overall survival in these pts. In this study the impact of abiraterone treatment and other subsequent salvage regimens after DC failure was analyzed. Methods: DC failure was defined as disease progression during DC treatment according to the Prostate Cancer Working Group (PCWG2 2007) criteria. Since February 2005, 74 consecutive DRPC pts were treated with at least 2 cycles DC until disease progression. At the time of the current analysis 67 pts have progressed and 41 pts received one or more subsequent therapies (1-3). Results: Overall survival (OS) of all 67 pts who have progressed during DC treatment was 7.1 months (CI 95% 1.8, 12.3). 41 pts received subsequent salvage therapies including mitoxantrone-prednisone-etoposide (MPE) (n=10), cabazitaxel (n=10), docetaxel-oxaliplatin (n=8), abiraterone (n=15) and doxorubicin-ketokonazol (n=5). OS of these 41 pts was 14.6 months (CI 95% 11.0, 18.3).In pts receiving abiraterone as salvage treatment, OS after DC was 21.8 months (CI 95% 7.2, 36.5) versus 11.9 months (CI 95% 9.0, 14.8) in pts receiving other regimens (HR 0.302, CI 95% 0.11, 0.8; p=0.016). Responses of prostate-specific antigen (PSAR; ≥30% and ≥50%) were only observed in pts receiving abiraterone (8/15, 53.3% and 4/15, 26.7%, respectively). Conclusions: Our data demonstrate for the first time that testosterone is an important prognostic factor for PSA response and OS in mDRPC patients receiving DC chemotherapy and that targeting testosterone after DC failure prolongs post-DC survival.

scholarly journals Effects of Eight-Week Combined Resistance and Endurance Training on Serum Levels of Prostate Specific Antigen (PSA), Sex Hormone Binding Globulin (SHBG), and Phosphatase and Tensin Homolog (PTEN) in Men with Prostate Cancer

2022 ◽  
Vol 19 (4) ◽  
Author(s):  
Abbas Jafari ◽  
Hamid Arazi ◽  
Amirabbas Monazzami ◽  
Alireza Ghadian ◽  
Kambiz Hasrak
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Training Group ◽  
Serum Levels ◽  
Sex Hormone Binding Globulin ◽  
Aerobic Performance ◽  
Control Group ◽  
Strength Performance ◽  
Combined Training ◽  
Tensin Homolog

Background: Prostate cancer (PC) is the second most prevalent cancer and the sixth cancer leading to death in men worldwide. Objectives: The purpose of this study was to examine the effect of eight weeks of combined training on specific markers of prostate cancer in older adults. Methods: Twenty older adults (62 ± 7 years) with prostate cancer were divided randomly into the control (n = 10) and training (n = 10) groups. The training group performed exercise training in three sessions a week for eight weeks. Resistance training included two sets of 10 repetitions at 60 - 75% of one-repetition maximum, and endurance training contained treadmill running for 20 - 35 min at 60 - 75% of maximum heart rate. Bruce test, one-repetition maximum, and ELISA technique were used respectively to measure the aerobic performance, strength performance, and serum levels of prostate specific antigen (PSA), sex hormone binding globulin (SHBG), phosphatase and tensin homolog (PTEN), and testosterone (TS). A two-way analysis of variance with repeated measures was used to specify the differences. Results: Weight, fat percentage, Body Mass Index (BMI), waist-hip ratio (WHR), glucose, insulin, and PSA were significantly lower in the training group than the control group (P < 0.05). Furthermore, strength performance, aerobic performance, SHBG, TS, and PTEN were significantly higher in the training group than in the control group (P < 0.05). Conclusions: Combined training can have an influential role in physical condition improvement through decreasing the PSA serum level and increasing SHBG, TS, and PETEN serum levels, which helps patients with prostate cancer to be cured.

Primary Fibrinolysis as the Presenting Sign of Metastatic Prostate Cancer: One Case Report and Literature Review.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3966-3966
Author(s):  
Rongfu Zhou ◽  
Jian Ouyang ◽  
Bing Chen ◽  
Ming Zhou ◽  
Yong Xu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Blood Cell ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Serum Levels ◽  
Fresh Frozen Plasma ◽  
Bone Lesions ◽  
Thrombin Time ◽  
Normal Range ◽  
Free Psa

Abstract Primary fibrinolysis revealing a prostatic adenocarcinoma is rare. Most of the case are limited to biological abnormalities. Here, we describe an unusual case of hematuria and primary fibriolysis as the presenting manifestation of metastatic prostate cancer in a 52-year-old man. The patient consulted for hematuria, ecchymosis and bleeding gums for a month. B-type ultrasound examination showed normal image of prostate. Peripheral blood test showed that the counts of white blood cell, red blood cell and platelet were all in normal range. APTT, prothrombin time and thrombin time were normal. But fibrinogen levels continued to lower than 1.1g/l despite infusions of cryoprecipitate and fresh frozen plasma. Further tests suggested that D-dimer was 9.58 mg/l (normal range: &lt;0.5mg/L), FDP 45 μg/ml, t-PA 90.30 ng/ml (1.00∼12.00 ng/ml), PAI-1 38.3 ng/ml (5.00∼45 ng/ml), α2-PI 118.00% (96.8∼118.8%), PLG 43.30% (57.8∼113.4%), prostate-specific antigen (PSA) 640.2 ng/ml (0∼4 ng/ml), Free PSA 64.2 ng/ml (0∼0.93 ng/ml). PET-CT revealed enhanced metabolizing rate of prostate with enlargement of lymph node in abdomen and multiple bone lesions including rib, vertebration and pelvis. Treatment with a luteinizing hormone-releasing hormone (LHRH) agonist (Diphereline) and a short course of an antiandrogen, led to normalization of all coagulation parameters within 2 weeks, and to clinical improvement and decline in the serum levels of PSA and fPSA. Three months later, the serum levels of PSA and fPSA were normal. We discuss the pathogenesis, differential diagnosis, and association of primary fibrinolysis with prostate cancer along with the management of this condition.

Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16064-e16064
Author(s):  
Michael A. Morgan ◽  
Martin Fenner ◽  
Viktor Grünwald ◽  
Axel S. Merseburger ◽  
Arnold Ganser ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Disease Progression ◽  
Salvage Therapy ◽  
Specific Antigen ◽  
Free Testosterone ◽  
Serum Levels ◽  
Castration Resistant Prostate Cancer ◽  
Psa Response ◽  
The Impact

e16064 Background: Our recent data have shown that carboplatin AUC5 on d1 plus docetaxel at a dose of 35 mg/m2 iv on d1, 8, 15 every 4 weeks (q4w) is an effective salvage therapy in mDRPC. Patients (pts) who have progressive disease during DC treatment survive only ~7 months and many are symptomatic. We have demonstrated that high free testosterone (FT) serum levels during DC treatment have a negative prognostic value for PSA response and overall survival in these pts. In this study the impact of abiraterone treatment and other subsequent salvage regimens after DC failure was analyzed. Methods: DC failure was defined as disease progression during DC treatment according to the Prostate Cancer Working Group (PCWG2 2007) criteria. Since February 2005, 74 consecutive DRPC pts were treated with at least 2 cycles DC until disease progression. At the time of the current analysis 69 pts have progressed and 43 pts received one or more subsequent therapies (1-3). Results: Overall survival (OS) of all 69 pts who have progressed during DC treatment was 8.0 months (CI 95% 3.7, 12.3). 43 pts received subsequent salvage therapies including mitoxantrone-prednisone-etoposide (MPE) (n=10), cabazitaxel (n=13), docetaxel-oxaliplatin (n=8), abiraterone (n=15), enzalutamide (n=5) and doxorubicin-ketokonazol (n=5). OS of these 43 pts was 14.6 months (CI 95% 11.0, 18.2).In pts receiving abiraterone as salvage treatment, OS after DC was 21.8 months versus 11.9 months (CI 95% 9.0, 14.8) in pts receiving other regimens (HR 0.17, CI 95% 0.07, 0.42; p<0.001). Responses of prostate-specific antigen (PSAR; ≥30% and ≥50%) were only frequently observed in pts receiving abiraterone (8/15, 53.3% and 4/15, 26.7%, respectively). Conclusions: Our data demonstrate for the first time that testosterone is an important prognostic factor for PSA response and OS in mDRPC patients receiving DC chemotherapy and that targeting testosterone after DC failure prolongs post-DC survival.

Sign in / Sign up

Export Citation Format

Share Document